Aua Capital Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 71.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 956 shares of the company’s stock after selling 2,363 shares during the period. Aua Capital Management LLC’s holdings in Johnson & Johnson were worth $119,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Ladenburg Thalmann Financial Services Inc. raised its position in Johnson & Johnson by 4.5% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 492,102 shares of the company’s stock valued at $56,714,000 after buying an additional 21,263 shares in the last quarter. HCR Wealth Advisors bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $1,700,000. AQR Capital Management LLC raised its position in Johnson & Johnson by 10.3% in the fourth quarter. AQR Capital Management LLC now owns 6,254,092 shares of the company’s stock valued at $720,534,000 after buying an additional 585,337 shares in the last quarter. Guggenheim Capital LLC raised its position in Johnson & Johnson by 10.5% in the fourth quarter. Guggenheim Capital LLC now owns 1,170,925 shares of the company’s stock valued at $134,903,000 after buying an additional 111,088 shares in the last quarter. Finally, Banco Santander S.A. bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $26,631,000. Hedge funds and other institutional investors own 66.10% of the company’s stock.

Johnson & Johnson (JNJ) traded up 0.31% during trading on Monday, reaching $133.04. 1,096,032 shares of the company’s stock traded hands. The company has a 50 day moving average price of $132.88 and a 200-day moving average price of $127.04. The company has a market cap of $357.08 billion, a PE ratio of 22.51 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same period last year, the business earned $1.74 EPS. The company’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.53%. Johnson & Johnson’s payout ratio is 56.76%.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/21/johnson-johnson-jnj-shares-sold-by-aua-capital-management-llc.html.

JNJ has been the subject of several recent research reports. Morgan Stanley lifted their price target on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 5th. BidaskClub lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.54 price target for the company. in a research report on Monday, May 1st. Jefferies Group LLC reiterated a “hold” rating and issued a $140.00 price target on shares of Johnson & Johnson in a research report on Friday, June 16th. Finally, Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $133.70.

In other news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.